C

CSL

Develops and delivers biotherapies and vaccines

Executive Director - Immunology Sales

Full-TimePosted on 10/22/2026
No salary listed
Expert
Bachelor's
King of Prussia, PA, USA
In PersonTravel required: 50%.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree in Business or Life Sciences.
  • A proven track record of success with 12 or more years of sales, sales management, and/or marketing/account management experience, with extensive knowledge of the healthcare environment, including healthcare systems, integrated delivery networks, specialty pharmacies, reimbursement, and funding mechanisms.
  • Experience in rare disease and immunology and/or neurology.
  • Experience developing strategic business plans and implementing omnichannel strategies through cross-functional teams in competitive markets.
  • Competencies include developing direct reports and others, directing others, drive for results, decision quality, strategic agility, business acumen, ethics and values, managerial courage, and building effective teams.
Responsibilities
  • Lead the Immunology/Neurology salesforce to achieve sales, operating expense, and market development goals in a profitable and compliant manner.
  • Develop strategies and tactics, in collaboration with Marketing, Corporate Accounts, Business Operations, and Medical Affairs, to deliver the business.
  • Establish productive relationships with external stakeholders, including immunologists, neurologists, healthcare professionals, and key opinion leaders.
  • Establish a high-performing team that communicates and promotes product clinical and economic benefits, builds and maintains relationships, educates healthcare staff, and identifies growth opportunities.
  • Cultivate national and regional relationships with key opinion leaders and advocacy groups to impact regional sales and elevate the company's reputation.
  • Develop multilevel and senior relationships within assigned accounts and affiliated organizations to support new business development.
  • Collaborate with other departments, including Marketing, Market Access, Medical Affairs, and Training, and serve as a subject matter expert on sales issues and strategy.
  • Create and execute a comprehensive competitive sales plan to meet or exceed U.S. sales goals for the Immunology/Neurology portfolio in line with organizational strategies and brand plans.
  • Manage the operating expense budget within target and ensure collaboration between the sales team and Corporate Accounts, Marketing, and Medical Affairs.
  • Serve as a core member of the immunology team developing strategies and initiatives that drive competitive advantage; lead sales planning and execution for cross-functional initiatives.
  • Support Marketing in developing and implementing programs that drive field-level sales and integrate marketing programs to achieve sales objectives.
  • Translate business strategy into operational goals and objectives; contribute to field sales performance standards, monitor progress, and adjust plans to meet company, regional, and customer needs.
  • Work with the VP of Sales and Sales Operations to determine salesforce sizing, alignment, deployment, and incentive program design; manage changes to these elements to minimize disruption, maintain engagement, and support cost-effective sales goals.
  • Identify opportunities to optimize sales team effectiveness.
  • Work with Sales Training to ensure the sales organization is trained in business acumen, product knowledge, and sales skills, and deliver personal development plans based on predetermined competencies.
  • Ensure the salesforce can use technology to deliver an omnichannel customer experience and use reporting tools to manage territories and regions.
  • Create a transparent, collaborative, trusting, and patient-centric culture; establish a fact-based and disciplined approach to accountability and ethical performance.
  • Ensure sales operations comply with company, industry, and government regulations.
  • Oversee and effectively manage team members, including setting annual objectives, conducting mid-year and year-end reviews, coaching and counseling, employee development, recruiting and selecting talent, directing and measuring work, providing timely constructive feedback, and ensuring work meets company standards and is customer-focused.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Oct 21st, 2026
CSL appoints ViiV Healthcare chief Deborah Waterhouse as CEO on $1.9M base salary

CSL Limited has appointed Deborah Waterhouse as chief executive officer and managing director, effective February 1, 2027. The board's decision followed a global search and was unanimous. Waterhouse has led ViiV Healthcare, an HIV specialist majority owned by GSK, since 2017. ViiV had sales of £7.7 billion in GSK's 2025 financial year. She also serves as president of GSK Global Health and previously ran GSK's US vaccines and primary care businesses. Her base salary will be £1,500,000 a year. She will stay based in the UK. Gordon Naylor will remain interim chief executive until then, before returning to the board as a non-executive director.

Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.